Quantcast

Latest Human Genome Sciences Stories

45470a48e55222091e42d5d625e445e61
2011-03-10 09:15:41

The US Food and Drug Administration (FDA) has approved Benlysta, making it the first new treatment for lupus to receive the agency's blessing in five decades. Benlysta is a drug that is taken by injection once per month. It is designed to help relieve pain and reduce the severity of symptoms associated with lupus--the mysterious disease in which the body's immune system turns on itself, attacking tissues and organs and leading to joint pain, chronic fatigue, arthritis, skin rashes, and in...

092fc1f823fd1b4d2ac75d740adcb9d71
2011-03-08 07:25:00

A drug for lupus, produced by Human Genome Sciences Inc., is set to get clearance from health regulators, bringing patients the first approved treatment in more than 50 years, and potentially bringing heavy revenue to the company. Analysts expect the Food and Drug Administration to approve Benlysta by Thursday. If approved, global sales could top $3 billion in 2015, according to Thomson Reuters consensus forecasts. The company will split Benlysta profits with partner GlaxoSmithKline Plc....

2011-03-01 08:00:00

HONG KONG, March 1 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Dendreon Corp. (NASDAQ: DNDN) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com. Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is...

2010-11-16 16:29:00

WASHINGTON, Nov. 16, 2010 /PRNewswire-USNewswire/ -- Today the U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend BENLYSTA® for approval as a treatment for the autoimmune disease lupus. If FDA approved, BENLYSTA would become the first new treatment for lupus in 52 years. While today's vote is a positive step, the FDA still must make a final decision to approve BENLYSTA in the coming weeks. Sandra C. Raymond,...

2010-10-14 16:16:00

WASHINGTON, Oct. 14 /PRNewswire/ -- The newly merged Lupus Foundation of America-DC/MD/VA Chapter (LFA-DC/MD/VA) at http://www.lupusdmv.org will launch wider chapter services in Virginia with the Second Annual Walk for Lupus Now! Richmond on Saturday, Oct. 30 at 3 p.m. at the Richmond International Raceway, 600 E. Laburnum Ave. The walk comes just before BENLYSTA -- the first drug for lupus in 52 years from walk sponsor Human Genome Sciences -- is expected to become available in December....

2010-05-13 01:05:00

WASHINGTON, May 13 /PRNewswire-USNewswire/ -- More than 600 people turned out tonight for the Lupus Foundation of America's (LFA) National Butterfly Gala, which recognized Ted Turner, Chairman, Turner Enterprises, Inc., Senator, Daniel K. Inouye (HI), Human Genome Sciences and GlaxoSmithKline for their contributions to advancing the science and medicine of lupus, and supporting the millions of people around the world affected by lupus. (Photo:...

2010-05-10 12:27:00

WASHINGTON, May 10 /PRNewswire/ -- The Lupus Foundation of America Greater Washington Chapter (LFAGW) set a nationwide chapter record for its 4th Annual Walk for Lupus Now! at http://www.dclupuswalk.org Washington, raising more than $250,000 with 2,500 walkers and $270,000 expected by the end of May. Corporate sponsor Human Genome Sciences (HGS) also set a team record donating more than $33,000, its highest team record ever. In time for today's World Lupus Day, HGS also made a generous...

2009-11-06 09:37:00

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus. "Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people...

2009-11-02 01:18:00

BENLYSTA(TM) Successful in Second Pivotal Clinical Trial WASHINGTON, Nov. 2 /PRNewswire-USNewswire/ -- Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in...

2009-11-02 00:23:00

Second successful phase III trial points to the first new lupus treatment in over 5O years. NEW YORK, Nov. 2 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related